» Articles » PMID: 31164554

Pseudotype Neutralization Assays: From Laboratory Bench to Data Analysis

Overview
Journal Methods Protoc
Specialty General Medicine
Date 2019 Jun 6
PMID 31164554
Citations 73
Authors
Affiliations
Soon will be listed here.
Abstract

Pseudotype neutralization assays are powerful tools to study functional antibody responses against viruses in low biosafety laboratories. However, protocols described in the literature differ widely with respect to material, reagents, and methods used to perform these assays and to analyse the raw data generated. This could result in discrepancies between the results of different laboratories even when the same pseudotypes and the same samples are analysed. Here, we describe, in detail, an experimental protocol to perform pseudotype neutralization assays using lentiviral pseudotypes bearing influenza haemagglutinin and expressing firefly luciferase. We also present the steps necessary to analyse the data and calculate the half maximal inhibitory concentration of the sera analysed. This protocol will provide support for the validation and the standardization of the pseudotype neutralization assay for influenza virus serology. Additionally, it will provide a starting point for the development of pseudotype neutralization assays using pseudotypes bearing other viral envelope proteins.

Citing Articles

Newcastle Disease Virus Displaying an Ectodomain of Middle East Respiratory Syndrome Coronavirus Spike Protein Elicited Robust Humoral and Cellular Immunity in Mice.

Prasopsiri J, Srisutthisamphan K, Liwnaree B, Jengarn J, Kramyu J, Hansoongnern P Vaccines (Basel). 2025; 13(1.

PMID: 39852781 PMC: 11768598. DOI: 10.3390/vaccines13010002.


A validated and standardized pseudotyped microneutralization assay as a safe and powerful tool to measure LASSA virus neutralising antibodies for vaccine development and comparison.

Antonelli R, Forconi V, Molesti E, Semplici C, Piu P, Altamura M F1000Res. 2024; 13:534.

PMID: 39512237 PMC: 11541077. DOI: 10.12688/f1000research.149578.2.


Immune signature in vaccinated versus non-vaccinated aged people with COVID-19 pneumonia.

Alessandra R, Sara C, Claudia P, Natasha G, Federica C, Chiara B J Transl Med. 2024; 22(1):755.

PMID: 39135151 PMC: 11318244. DOI: 10.1186/s12967-024-05556-2.


Antibody responses in blood and saliva post COVID-19 bivalent booster do not reveal an Omicron BA.4/BA.5- specific response.

Baker Jr R, Lawlor R, Smith M, Price J, Eaton A, Lover A Front Immunol. 2024; 15:1401209.

PMID: 38812500 PMC: 11133519. DOI: 10.3389/fimmu.2024.1401209.


Development of a Candidate TMV Epitope Display Vaccine against SARS-CoV-2.

Phiri K, Grill L Vaccines (Basel). 2024; 12(5).

PMID: 38793699 PMC: 11125883. DOI: 10.3390/vaccines12050448.


References
1.
Temperton N, Hoschler K, Major D, Nicolson C, Manvell R, Hien V . A sensitive retroviral pseudotype assay for influenza H5N1-neutralizing antibodies. Influenza Other Respir Viruses. 2009; 1(3):105-12. PMC: 4941878. DOI: 10.1111/j.1750-2659.2007.00016.x. View

2.
Corti D, Voss J, Gamblin S, Codoni G, Macagno A, Jarrossay D . A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science. 2011; 333(6044):850-6. DOI: 10.1126/science.1205669. View

3.
Ferrara F, Molesti E, Bottcher-Friebertshauser E, Cattoli G, Corti D, Scott S . The human Transmembrane Protease Serine 2 is necessary for the production of Group 2 influenza A virus pseudotypes. J Mol Genet Med. 2013; 7:309-14. PMC: 3614188. View

4.
Krammer F, Palese P . Influenza virus hemagglutinin stalk-based antibodies and vaccines. Curr Opin Virol. 2013; 3(5):521-30. PMC: 3804342. DOI: 10.1016/j.coviro.2013.07.007. View

5.
Sarzotti-Kelsoe M, Bailer R, Turk E, Lin C, Bilska M, Greene K . Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1. J Immunol Methods. 2013; 409:131-46. PMC: 4040342. DOI: 10.1016/j.jim.2013.11.022. View